Date: 2016-10-27
Type of information: Nomination
Compound:
Company: Erytech Pharma (France)
Therapeutic area: Cancer - Oncology - Rare diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On October 27, 2016, Erytech Pharma announced the appointments of Dr. Alexander Scheer, Ph.D. as the company’s Chief Scientific Officer and Jean-Sébastien Cleiftie, as Chief Business Officer. Dr. Scheer has over 15 years of experience in R&D and the life science industry. Prior to joining Erytech, he served as the Head of Research at Pierre Fabre in France, focused primarily on oncology and central nervous system research, and also served as a Deputy Head of Research at Pierre Fabre. Prior to joining Pierre Fabre, Dr. Scheer served as a Director, Global Research Informatics & Knowledge Management R&D and Project Leader, Neglected Diseases at Merck Serono in Switzerland where, among other responsibilities, he led Merck’s program to develop drugs for neglected diseases in collaboration with the World Health Organization (WHO). He also served as Head of Molecular Screening and Cellular Pharmacology Department, Group Leader of Biochemical Pharmacology and Research Scientist at Serono. Dr. Scheer holds a B.Sc in Natural Sciences and M.Sc. in Chemistry, both from the University of Gottingen, and a Ph.D. in Chemistry and Biochemistry from the German Cancer Research Center. Mr. Cleiftie brings 15 years of experience in drug development, life science venture capital, and business development and licensing within the U.S. and European biopharmaceutical ecosystem. Prior to joining Erytech, he served as Associate Vice-President, Global Business Development & Licensing at Sanofi in Paris, France, where he led licensing transactions across multiple therapeutic areas, financial valuation activities, and other strategic projects. Prior to joining Sanofi, Mr. Cleiftie was a Principal at Innoven Partners, a venture capital firm active as lead investor in healthcare and IT in Europe and the U.S. He was responsible for healthcare investment opportunity assessment, transaction execution, and active portfolio management, and led equity investments in a number of biotech and medtech companies which achieved successful exits. He started his career in drug development in the U.S. as a research scientist with Aventis (now Sanofi) in the fields of immunotherapy and gene therapy for cancer. Mr. Cleiftie earned a M.S. in Biological & Medical Sciences and a M.S. in Immunology from the University of Paris V, and received his M.B.A from Cornell University.
Financial terms:
Latest news:
